| Stonecreek Family Physicians, Llp | |
|
4101 Anderson Ave Manhattan KS 66503-7588 | |
| (785) 587-4101 | |
| (785) 587-9090 |
| Full Name | Stonecreek Family Physicians, Llp |
|---|---|
| Speciality | Family Medicine |
| Location | 4101 Anderson Ave, Manhattan, Kansas |
| Authorized Official Name and Position | Kevin K Wall (PARTNER) |
| Authorized Official Contact | 7855874101 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Stonecreek Family Physicians, Llp 4101 Anderson Ave Manhattan KS 66503-7588 Ph: (785) 587-4101 | Stonecreek Family Physicians, Llp 4101 Anderson Ave Manhattan KS 66503-7588 Ph: (785) 587-4101 |
| NPI Number | 1093828097 |
|---|---|
| Provider Enumeration Date | 08/16/2006 |
| Last Update Date | 09/29/2021 |
| Medicare PECOS PAC ID | 9335121565 |
|---|---|
| Medicare Enrollment ID | O20040602001030 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093828097 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (Kansas) | Primary |
| Provider Name | Kevin K Wall |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1285673087 PECOS PAC ID: 7113983180 Enrollment ID: I20041202000234 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Douglas P Hinkin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720027527 PECOS PAC ID: 1355307323 Enrollment ID: I20041202000257 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Keith A Wright |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174562227 PECOS PAC ID: 9133185119 Enrollment ID: I20041202000289 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Debra Lynn Doubek |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1588619910 PECOS PAC ID: 8628034600 Enrollment ID: I20041202000327 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Jacqi I Lambert |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467407569 PECOS PAC ID: 2961468848 Enrollment ID: I20041202000356 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Kent H Kiracofe |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1285689380 PECOS PAC ID: 0840256723 Enrollment ID: I20041202000382 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Ryan C Knopp |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1427003409 PECOS PAC ID: 4284690181 Enrollment ID: I20041202000471 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Amy R Cunningham |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1902855661 PECOS PAC ID: 9133185960 Enrollment ID: I20061214000246 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Danelle L Perry |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1881738052 PECOS PAC ID: 4082717764 Enrollment ID: I20070319000173 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Lindsey A Westberg |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467616896 PECOS PAC ID: 1759559834 Enrollment ID: I20110715000036 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Melissa Rosso |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720216708 PECOS PAC ID: 6507000908 Enrollment ID: I20130925000778 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Bethany Anne Duff |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750675724 PECOS PAC ID: 3072751783 Enrollment ID: I20140919001099 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Lacey Leigh Schuckman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427457597 PECOS PAC ID: 3971821117 Enrollment ID: I20150417001855 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Jason L Hoke |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1992969661 PECOS PAC ID: 6507196300 Enrollment ID: I20190920001972 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Adam Zuzelski |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891351136 PECOS PAC ID: 1759763295 Enrollment ID: I20220801001626 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Sarah Elizabeth Lewis Gish |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1124245915 PECOS PAC ID: 3476872888 Enrollment ID: I20230506000228 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
| Provider Name | Christopher Hazen Short |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1689024382 PECOS PAC ID: 7315235074 Enrollment ID: I20231129002627 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
News Archive
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.
Children with cancer have a higher prevalence of body abnormalities, such as asymmetric lower limbs and curvature of the spine, suggesting that the genetic defect responsible for the abnormality may play a role in the development of cancer, according to a study in the January 2 issue of JAMA.
Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.
For the fifth consecutive year, the Commonwealth Fund listed the U.S. last in a ranking of health systems of Western industrialized nations. The rankings looked at quality, outcomes and efficiency.
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
› Verified 5 days ago
Smith Internal Medicine, P.a. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3260 Kimball Ave, Manhattan, KS 66503 Phone: 785-539-0800 Fax: 785-539-0811 | |
Dr James Gardner Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1133 College Ave, Suite D200, Manhattan, KS 66502 Phone: 785-537-4940 Fax: 785-537-0836 | |
Matthew W Floersch, M.d., Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1133 College Ave, Suite C-143, Manhattan, KS 66502 Phone: 785-537-4940 Fax: 785-537-0836 | |
Manhattan Primary Care Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1133 College Ave, Bldg A, Suite 211, Manhattan, KS 66502 Phone: 913-642-4900 Fax: 913-381-0979 | |
Primary Care Physicians Of Manhattan Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1133 College Ave, Suite C-143, Manhattan, KS 66502 Phone: 785-537-4940 Fax: 785-537-0836 | |
Midwest Prompt Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3258 Kimball Ave, Manhattan, KS 66503 Phone: 785-539-0800 Fax: 785-539-0811 |